Search
Now showing items 1-9 of 9
Nanomedicines for infectious diseases
(Springer Nature, 2019)
Infectious diseases continue to pose a significant threat to global health. Over 200 infectious diseases are currently known to man. Fortunately, only a handful are responsible for significant morbidity and mortality. ...
Establishment of the African Medicines Agency: Progress, challenges and regulatory readiness
(Springer Nature, 2021)
Insufcient access to quality, safe, efcacious and afordable medical products in Africa has posed a signifcant challenge to public health for decades. In part, this is attributed to weak or absent policies and regulatory ...
Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin
(Royal Society of Chemistry, 2020)
Antibiotic resistance is increasing at such an alarming rate that it is now one of the greatest global health challenges. Undesirable toxic side-effects of the drugs lead to high rates of non-completion of treatment regimens ...
Medicines regulatory science expertise in Africa: workforce capacity development and harmonisation activities towards the establishment of the African medicines agency
(Adis, 2022)
The medicines regulatory landscape in Africa is undergoing transformation with at least two countries having National Medicines Regulatory Authorities (NRAs) that operate at World Health Organization (WHO) maturity level ...
Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
(Elsevier, 2022)
Tuberculosis (TB) remains one of the deadliest communicable dis-
eases caused by Mycobacterium tuberculosis (Mtb) since its discovery in
the 1880s (Cambau and Drancourt, 2014; Singh et al., 2020). Over 1
billion mortalities ...
Situation analysis on the regulation of nanomedicines in Southern Africa
(Frontiers Media, 2023)
Medical products incorporating nanoparticle drug delivery
systems (nanomedicines) are therapeutic or imaging agents, which comprise
a delivery system within the nanometer size range (1 – 1000 nm). As medical
products, ...
Preparation and evaluation of pralidoxime-loaded plga nanoparticles as potential carriers of the drug across the blood brain barrier
(Hindawi, 2015)
Pralidoxime is an organophosphate antidote with poor central nervous system distribution due to a high polarity. In the present
study, pralidoxime-loaded poly(lactic-co-glycolic acid) nanoparticles were prepared and ...
Comparative study on the topical and transdermal delivery of diclofenac incorporated in nano-emulsions, nano-emulgels, and a colloidal suspension
(Springer, 2022)
Transdermal delivery of active pharmaceutical ingredients (APIs) can be challenging, since the skin possesses a rate-limiting barrier, which may be overcome when APIs possess certain ideal physicochemical properties. The ...
The domestication of the African union model law on medical products regulation: perceived benefits, enabling factors, and challenges
(Frontiers Media, 2023)
Introduction: In 2016, the African Union (AU) Model Law on Medical Products Regulation was endorsed by AU Heads of State and Government. The aims of the legislation include harmonisation of regulatory systems, increasing ...